Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know

Key Takeaways ZTS shares slump YTD as safety issues with Librela and Solensia cause sales declines and guidance cuts.FDA reviews and new analyses highlight higher adverse events in Librela-treated dogs versus other OA drugs.ZTS leans on parasiticides, dermatology and new long-acting OA therapies to support a potential 2026 rebound.Shares of Zoetis (ZTS) have plunged 24.8% year to date, amid mounting safety concerns surrounding its monoclonal antibody osteoarthritis (OA)pain therapies — Librela for dogs and ...